Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.

Bioactive coatings suitable for facilitating removal of a fingerprint when contacting the coating are provided including a base associated with a chemically modified enzyme, and, optionally a first polyoxyethylene present in the base and independent of the enzyme. The coatings are optionally overlayered onto a substrate. Also provided are processes of facilitating fingerprint removal.

Bioactive coatings suitable for facilitating removal of a fingerprint when contacting the coating are provided including a base associated with a chemically modified enzyme, and, optionally a first polyoxyethylene present in the base and independent of the enzyme. The coatings are optionally overlayered onto a substrate. Also provided are processes of facilitating fingerprint removal.

Provided herein is a non-naturally occurring microbial organism (NNOMO) having a methanol metabolic pathway (MMP) that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as succinate. Also provided herein are methods for using such an organism to produce succinate.

The invention provides methods and systems by which enzymes can be modified to improve solubility, catalytic activity, recoverability, and recyclability. The enzyme may be modified with a thermosensitive copolymer to form an enzyme-polymer conjugate that exhibits upper critical solution temperature (UCST) and/or lower critical solution temperature (LCST)-type behavior in an organic solvent, ionic liquid, or other solvent. Methods and systems of the invention facilitate the use of enzymes as biocatalysts in solvents.

The invention provides methods and systems by which enzymes can be modified to improve solubility, catalytic activity, recoverability, and recyclability. The enzyme may be modified with a thermosensitive copolymer to form an enzyme-polymer conjugate that exhibits upper critical solution temperature (UCST) and/or lower critical solution temperature (LCST)-type behavior in an organic solvent, ionic liquid, or other solvent. Methods and systems of the invention facilitate the use of enzymes as biocatalysts in solvents.

Disclosed is a composition comprising a nicking enzyme and a water-soluble rubidium salt, and a method of performing a reaction catalysed by a nicking enzyme including the presence of a water-soluble rubidium salt in the reaction.

Disclosed herein are formulations with improved stability or reduced viscosity that comprise a therapeutic protein and a lyo-enhancing excipient, wherein the improved stability formulation is characterized by improved stability in comparison to a control formulation otherwise identical to the stability-enhanced formulation but lacking the lyo-enhancing excipient, and the reduced viscosity formulation is characterized by reduced viscosity in comparison to a control formulation otherwise identical to the reduced viscosity formulation but lacking the lyo-enhancing excipient. Further disclosed herein are methods of improving stability of therapeutic formulations, reducing viscosity of therapeutic formulations, or improving parameters of lyophilization processes.

Disclosed herein are formulations with improved stability or reduced viscosity that comprise a therapeutic protein and a lyo-enhancing excipient, wherein the improved stability formulation is characterized by improved stability in comparison to a control formulation otherwise identical to the stability-enhanced formulation but lacking the lyo-enhancing excipient, and the reduced viscosity formulation is characterized by reduced viscosity in comparison to a control formulation otherwise identical to the reduced viscosity formulation but lacking the lyo-enhancing excipient. Further disclosed herein are methods of improving stability of therapeutic formulations, reducing viscosity of therapeutic formulations, or improving parameters of lyophilization processes.

The present invention provides a protein aggregation inhibitor for use in preventing aggregation of a protein, containing a crosslinked polymer obtained by polymerizing polymerizable polymer components containing a sulfobetaine polymer obtained by polymerizing monomer components containing a sulfobetaine monomer, the sulfobetaine monomer, and a crosslinkable monomer.